R-21

N/A

Report date: 2026/03/12 20:00:16

Base Information

Drug NameR-21
Drug Alias NameMalaria virus-like particle vaccine(MultiMalVax)Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine(Multimalvax)R21/Matrix-M adjuvanted malaria vaccineR21/Matrix-M™ malaria vaccineR21/Matrix-M +[8] 
ClassificationVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsVector Borne DiseasesMalaria, FalciparumMalaria +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUgandaThailandUnited Kingdom +[7] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcUniversity Of OxfordNovavax
China Registration ClassN/A

Develop Information

Active CompaniesSerum Institute Of India Pvt LtdUniversity Of OxfordLondon School Of Hygiene And Tropical Medicine +[4] 
Inactive CompaniesN/A
Active IndicationsVector Borne DiseasesMalaria, FalciparumMalaria +[5] 
Inactive IndicationsInfections

Other Information

ATC CodeN/A
Related LinksN/A